Navigation Links
Physics provides new insights on cataract formation
Date:11/9/2007

Using the tools and techniques of soft condensed matter physics, a research team in Switzerland has demonstrated that a finely tuned balance of attractions between proteins keeps the lens of the eye transparent, and that even a small change in this balance can cause proteins to aggregate and de-mix. This leads to cataract formation, the worlds leading cause of blindness. This work could shed light on other protein aggregation diseases (such as Alzheimers disease), and may one day lead to methods for stabilizing protein interactions and thus preventing these problematic aggregations from occurring.

The eye lens is made up of densely packed crystallin proteins, arranged in such a way that light in the visible wavelength range can pass through. But for a variety of reasons including UV radiation exposure and age, the proteins sometimes change their behavior and clump together. As a result, light is scattered once it enters the lens, resulting in cloudy vision or blindness. There is currently no known way to reverse the protein aggregation process once it has begun. Nearly 5 million people every year undergo cataract surgery in which their lenses are removed and replaced with artificial ones.

Previous research has shown that the interactions between the three major crystallin proteins that make up the concentrated eye lens protein solution are key to cataract formation. A team of scientists from the University of Fribourg, EPFL and the Rochester Institute of Technology (USA) studied the interactions between two of these proteins, at concentrations similar to those found in the eye lens, using a combination of neutron scattering experiments and molecular dynamics computer simulations. They found that a finely tuned combination of attraction and repulsion between the two proteins resulted in an arrangement that was transparent to visible light. By combining experiments and simulations it became possible to quantify that there had to be a weak at
'/>"/>

Contact: Mary Parlange
mary.parlange@epfl.ch
41-216-937-022
Ecole Polytechnique Fdrale de Lausanne  
Source:Eurekalert

Page: 1 2

Related medicine news :

1. SNM/Nihon Medi-Physics sponsor new fellowship program for Japanese physicians
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. USAID Provides Additional Wildfire Assistance to Greece
5. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
6. New knock-out gene model provides molecular clues to breast cancer
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. SIV infection of natural hosts provides new insights into HIV disease complexity
9. Microarray provides 3 genomic guides to breast cancer treatment decisions
10. Access Innovations Provides Support Services for Agis Network
11. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Physics provides new insights on cataract formation
Physics provides new insights on cataract formation
(Date:12/3/2009)..., , SOUTHBRIDGE, Mass., Dec. 3 /PRNewswire/... approval to treat its first patients, Harrington ...t seeing patients immediately," said Diane Becquar..., The approval was granted today by the Massachu...ty and quality review of the facility. ,, The ...
(Date:12/3/2009)..., , BEIJING, Dec. 3 /PRNewswire-Asia/...enefits, ginger, one of the most important ingredi...in China during this flu season. , The ti... supply shortages,effecting upward price pressure...potential repeat of the current demand hysteria ov...
(Date:12/3/2009)..., , SILVER SPRING, Md., Dec. 3 /PRNewsw...g a health care system that ensures affordable, qu...on urges all Americans to contact their representa...h care reform. ,, See video from ANA at: http:...dvocating for a health care system that focuses on...
(Date:12/3/2009)...Roles of aggressor, victim often play out at schoo...c. 3 (HealthDay News) -- School bullies are also l... according to an Italian study that included 195 c...rticipants -- all with a sibling no more than four...ether they bullied or were bullied at school or at...
(Date:12/3/2009)...Finding could aid in eventual development of scree...DAY, Dec. 3 (HealthDay News) -- New research point...amin D and heart disease. , People with high bl...itamin D activation in the body were found to be t...e congestive heart failure, the study found. , ...
Breaking Medicine News(10 mins):Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:VIDEO from Medialink and the American Nurses Association (ANA): American Nurses Association Urges All Americans to Take Part in Health Care Reform Debate 2Health News:Bullies May Intimidate Siblings, Too 2Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2
...anizations are turning to Amalga to connect hospit...h centers., REDMOND, Wash., June 24 To improve t...to medically underserved,D.C. residents, the Distr... hospitals and six community-based health,centers ...
...COUVER, June 24 /PRNewswire-FirstCall/ - Beeston E...BB: BESE) announces that it completed,drilling on ... from,Candorado Operating Company Ltd. (TSX Ventur... copper-gold deposits., The Company is carrying o...
...New evidence-based guidelines address the preventi...ulations and reinforce recommendations related to ... as a supplement in the June issue of CHEST , the...ice Guidelines, Eighth Edition was developed by an...
...cuity,s Release of PriceAdvisor Combats Ineffectiv...action & Improve Revenue Projection and Recovery ...HILLS, Ill. and DUBLIN, Ireland, June 24 /PRNewswi...ology ("Peer,Reviewed by HFMA") and services, toda...
...tery shoppers allow providers to compare real expe...pectations., DALLAS, June 24 Mystery shopping go... why patients leave -- sometimes without,ever meet...come patients because they dismiss a healthcare or...
...3M Health Care today announced the launch of the 3...cal mask to meet the needs of clinicians seeking a...urgical mask incorporates proprietary filtration m... design, the 3M Filtron 1900 surgical mask provide...
Other Medicine News:Health News:District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved 2Health News:District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved 3Health News:Beeston completes drilling on Bluff Lake property, 100 Mile House 2Health News:New blood clot guidelines for pregnant women 2Health News:New blood clot guidelines for pregnant women 3Health News:New blood clot guidelines for pregnant women 4Health News:Concuity Announces the Availability of PriceAdvisor 2Health News:Concuity Announces the Availability of PriceAdvisor 3Health News:Concuity Announces the Availability of PriceAdvisor 4Health News:New White Paper from The Beryl Institute: 'Mystery Shopping the Patient Experience' 2Health News:3M Health Care launches new high-performance surgical mask 2
(Date:12/3/2009)... Dec. 3 ParagonRx, a Delaware-base...gement and optimal medication use, will host a fre... guidance on REMS - Risk Evaluation Mitigation Str...ecycle management. Dr. Gary Slatko, chief medical...sk management programs, will lead the one-hour pro...
(Date:12/3/2009)... Cardium Therapeutics (NY...ned subsidiary, Tissue Repair Company, submitted a.... Food and Drug Administration (FDA) seeking marke...didate based on positive data from the Company,s r... Today,s submission with the FDA covers Excellagen...
(Date:12/3/2009)...lif., Dec. 3 Each year, ... United States (U.S.) and Europe participate in th...ry experience under renowned faculty members at th...holars - past, present and future - will have excl...y at www.amgenscholars.com . ,, "The new Web ...
Breaking Medicine Technology:Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 2New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 1Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 11Maternal HIV 1 treatment protects against transmission to newborns 59640 1Maternal HIV 1 treatment protects against transmission to newborns 59640 2University of the Basque Country study on proteins related to Alzheimers 10397 1University of the Basque Country study on proteins related to Alzheimers 10397 2
...LES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corpora...gaged in the,development and commercialization of ... from the six-month, open-label extension,of its c... in ALS,volunteers. While the clinical trial was n...e three times daily appeared to be safe,and well-t...
...e Netherlands, June 27, 2007-Organon, the human,he...day that two,out of three Phase III clinical trial...g-acting fertility hormone, have reached,their ran...ew recombinant fertility hormone. It is,the first ...cular,stimulant or SFS) of which, due to its long ...
Other Medicine Technology:CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 2CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 3CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 4CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS 5Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
Medium Clip Appliers
Li Brand™ Surgical Hemostat
The 2201
No Scalpel Vasectomy Hemostat
Medicine Products: